-
Key Brands
-
Statistics
-
Revenue
-
Contribution
-
Analysis
| Brand | Therapeutic category |
|---|---|
|
Circadin |
Hormonal hypnotic sedative |
|
Eltroxin |
Thyroid hormone replacement |
|
Maltofer |
Iron supplement |
|
Marcaine |
Regional and spinal anaesthetic |
|
Xylocaine |
Regional anaesthetic |
0
Products
Launched
Launched
(2021: 2)
Product
Recalls
Recalls
(2021: Nil)
0
%
Average Staff
Turnover
Turnover
(2021: 8%)
Work-related
Facilities
Facilities
(2021: Nil)
435
Sales
Representatives
Representatives
(2021: 74)
200
Permanent
Employees
Employees
(June 2021: 538)
| Revenue |
2022 R’million |
2021 (CER) R’million |
Change % |
|---|---|---|---|
|
Commercial Pharmaceuticals |
5 103 |
4 680 |
9 |
|
Regional Brands |
4 464 |
3 955 |
13 |
|
Sterile Focus Brands |
643 |
725 |
(11) |
|
Manufacturing – FDF |
596 |
532 |
12 |
|
Total |
5 703 |
5 212 |
9 |
Note: Commercial Pharmaceuticals revenue is by customer geography and manufacturing revenue is by place of manufacture.
Contribution to Group revenue (%)
- Rest of Group 85
- Australasia 15
Revenue by segment (%)
- Regional Brands 79
- Sterile Focus Brands 11
- Manufacturing - FDF 10
- The Australia and New Zealand OTC market was valued at AUD4,5 billion in June 2022 and grew 12,9% driven by recovery of various therapeutic segments specifically the Cough/Cold/Flu and related segments as a result of stay-at-home COVID-19 treatments and severe cold and flu season.
- The total pharmaceutical segment excluding the grocery channel grew 9,2% June 2022.
Source: IQVIA June 2022
